Description:
Technology
Overview
The
TR BAC was prepared from the TR clinical HCMV isolate. This virus is resistant
to ganciclovir and cidofovir and lacks UL97 codons 591-594. The BAC clone
was generated by substituting BAC DNA for the US2-US5 region of the TR genome.
The TR strain infects almost any diploid endothelial or epithelial cell as well
as macrophages. This strain is useful for studies on HCMV including
genetic studies.
Publication
Proc
Natl Acad Sci U S A.
2003 Dec 9;100(25):14976-81 "Coding potential of laboratory and clinical strains
of human cytomegalovirus"
Inventor
Profile
Dr.
Jay Nelson joined the Oregon Health & Science University as a Professor in
the Department of Molecular Microbiology and Immunology in 1992. He was also the
Head of Pathobiology and Immunology at the Oregon National Primate Research
Center from 1998 to 2000. He is currently the Director of the Vaccine and Gene
Therapy Institute and holds joint appointments at the Oregon National
Primate Research Center and the Department of Molecular Microbiology and
Immunology.
Dr.
Michael Jarvis received his MS (1995) and Ph.D. (1996) in Biochemistry and
Molecular Biology from the University of California at Davis in the laboratory
of Dr. J. S. Powell. After conducting his postdoctoral studies under the
guidance of Dr. J. A. Nelson, Dr. Jarvis accepted a position as an Assistant
Scientist with OHSU at the Vaccine and Gene Therapy Institute in January of
2002.
Licensing
Opportunity
OHSU
1222 is currently available for non-exclusive licensing as a research
tool.
